In 2023 ESMO TAT will be dedicated to improving the conduct of early anti-cancer clinical trials, bringing together those who are developing the most promising new cancer drugs and unveiling exciting new data.
Stakeholders from academia and industry will discuss with clinicians, researchers, and regulators the global dissemination of knowledge and clinical research expertise in the field of innovative cancer therapeutics, to the benefit of cancer patients worldwide